These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 34632252)

  • 1. Clinical Outcomes of Molecular Tumor Boards: A Systematic Review.
    Larson KL; Huang B; Weiss HL; Hull P; Westgate PM; Miller RW; Arnold SM; Kolesar JM
    JCO Precis Oncol; 2021 Jul; 5():. PubMed ID: 34632252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Tumor Boards in Clinical Practice.
    Luchini C; Lawlor RT; Milella M; Scarpa A
    Trends Cancer; 2020 Sep; 6(9):738-744. PubMed ID: 32517959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pragmatic nationwide master observational trial based on genomic alterations in advanced solid tumors: KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II study protocol KCSG AL-22-09.
    Kim SY; Kim JH; Kim TY; Park SR; Yoon S; Lee S; Lee SH; Kim TM; Han SW; Kim HR; Yun H; Lee S; Kim J; Choi YL; Choi KS; Chae H; Ryu H; Lee GW; Zang DY; Ahn JB
    BMC Cancer; 2024 May; 24(1):574. PubMed ID: 38724991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next-Generation Sequencing in Oncology in the Era of Precision Medicine.
    Blumenthal GM; Mansfield E; Pazdur R
    JAMA Oncol; 2016 Jan; 2(1):13-4. PubMed ID: 26540172
    [No Abstract]   [Full Text] [Related]  

  • 6. Reasons to be testing: the dawn of complex molecular profiling in routine oncology practice.
    Beer PA; Cooke SL; Chang DK; Biankin AV
    Ann Oncol; 2019 Nov; 30(11):1691-1694. PubMed ID: 31665210
    [No Abstract]   [Full Text] [Related]  

  • 7. Feasibility and outcome of reproducible clinical interpretation of high-dimensional molecular data: a comparison of two molecular tumor boards.
    Rieke DT; de Bortoli T; Horak P; Lamping M; Benary M; Jelas I; Rüter G; Berger J; Zettwitz M; Kagelmann N; Kind A; Fabian F; Beule D; Glimm H; Brors B; Stenzinger A; Fröhling S; Keilholz U
    BMC Med; 2022 Oct; 20(1):367. PubMed ID: 36274133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pediatric oncology enters an era of precision medicine.
    Seibel NL; Janeway K; Allen CE; Chi SN; Cho YJ; Glade Bender JL; Kim A; Laetsch TW; Irwin MS; Takebe N; Tricoli JV; Parsons DW
    Curr Probl Cancer; 2017; 41(3):194-200. PubMed ID: 28343740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes after targeted treatment based on somatic tumor genetic testing for women with gynecologic cancers.
    Somasegar S; Hoppenot C; Kuchta K; Sereika A; Khandekar J; Rodriguez G; Moore E; Hurteau J; Vogel TJ
    Gynecol Oncol; 2021 Nov; 163(2):220-228. PubMed ID: 34511240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center.
    Tafe LJ; Gorlov IP; de Abreu FB; Lefferts JA; Liu X; Pettus JR; Marotti JD; Bloch KJ; Memoli VA; Suriawinata AA; Dragnev KH; Fadul CE; Schwartz GN; Morgan CR; Holderness BM; Peterson JD; Tsongalis GJ; Miller TW; Chamberlin MD
    Oncologist; 2015 Sep; 20(9):1011-8. PubMed ID: 26205736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Considerations of developing an NGS assay for clinical applications in precision oncology: The NCI-MATCH NGS assay experience.
    Lih CJ; Takebe N
    Curr Probl Cancer; 2017; 41(3):201-211. PubMed ID: 28625332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world patterns on tumor mutation burden testing in a pan-tumor population.
    Gautam S; Kachroo S; DeClue RW; Fisher MD; Basu A
    Future Oncol; 2021 May; 17(15):1879-1887. PubMed ID: 33512239
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of a Collaboration Between a Health Plan, Oncology Practice, and Comprehensive Genomic Profiling Company from the Payer Perspective.
    Reitsma M; Fox J; Borre PV; Cavanaugh M; Chudnovsky Y; Erlich RL; Gribbin TE; Anhorn R
    J Manag Care Spec Pharm; 2019 May; 25(5):601-611. PubMed ID: 30632889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Precision oncology: current and future platforms for treatment selection.
    Tang X; Berger MF; Solit DB
    Trends Cancer; 2024 Sep; 10(9):781-791. PubMed ID: 39030146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Giving Up on Precision Oncology? Not So Fast!
    Warner JL
    Clin Transl Sci; 2017 May; 10(3):128-129. PubMed ID: 28146309
    [No Abstract]   [Full Text] [Related]  

  • 16. The Molecular Tumor Board of the Regina Elena National Cancer Institute: from accrual to treatment in real-world.
    Giacomini P; Valenti F; Allegretti M; Pallocca M; De Nicola F; Ciuffreda L; Fanciulli M; Scalera S; Buglioni S; Melucci E; Casini B; Carosi M; Pescarmona E; Giordani E; Sperati F; Jannitti N; Betti M; Maugeri-Saccà M; Cecere FL; Villani V; Pace A; Appetecchia M; Vici P; Savarese A; Krasniqi E; Ferraresi V; Russillo M; Fabi A; Landi L; Minuti G; Cappuzzo F; Zeuli M; Ciliberto G
    J Transl Med; 2023 Oct; 21(1):725. PubMed ID: 37845764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Revisiting the Implications of Positive Germline Testing Results Using Multi-gene Panels in Breast Cancer Patients.
    Tsaousis GN; Papadopoulou E; Agiannitopoulos K; Pepe G; Tsoulos N; Boukovinas I; Floros T; Iosifidou R; Katopodi O; Koumarianou A; Markopoulos C; Papazisis K; Venizelos V; Kapsimalis A; Xepapadakis G; Psyrri A; Banu E; Eniu DT; Blidaru A; Stanculeanu DL; Ungureanu A; Ozmen V; Tansan S; Tekinel M; Yalcin S; Nasioulas G
    Cancer Genomics Proteomics; 2022; 19(1):60-78. PubMed ID: 34949660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Precision medicine beyond medical oncology: using molecular analysis to guide treatments of colorectal neoplasia.
    Molloy MP; Engel A
    Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1179-1181. PubMed ID: 30791786
    [No Abstract]   [Full Text] [Related]  

  • 19. Concordance in Molecular Tumor Board Case Reviews in the ASCO TAPUR Study.
    Perez JK; Kleber J; Rothe M; Mangat P; Garrett-Mayer E; Schilsky RL
    JCO Precis Oncol; 2024 Mar; 8():e2300615. PubMed ID: 38564684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New ESMO scale ranks mutations as cancer medicine targets.
    Fricker J
    Lancet Oncol; 2018 Oct; 19(10):e513. PubMed ID: 30177495
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.